Baxter International Inc.’s in-house team capitalized on its story-telling talent to win approval of last year’s $3.9 billion acquisition involving complicated medical technology to treat kidney disease.
The legal team had to explain the complex details of peritoneal dialysis and hemodialysis businesses to antitrust officials in the United States, European Union and other jurisdictions around the globe, clearing the way for the company’s purchase of Swedish medical-device maker Gambro A.B.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
